Filing Details
- Accession Number:
- 0000886163-18-000007
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-01-22 19:23:10
- Reporting Period:
- 2018-01-19
- Accepted Time:
- 2018-01-22 19:23:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 886163 | Ligand Pharmaceuticals Inc | LGND | Pharmaceutical Preparations (2834) | 770160744 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1208906 | L John Higgins | 3911 Sorrento Valley Boulevard, Ste 110 San Diego CA 92121 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-01-19 | 16,249 | $16.14 | 162,299 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-01-19 | 16,249 | $155.00 | 146,050 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-01-19 | 11,850 | $151.92 | 134,200 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Incentive Stock Option (right to buy) | Disposition | 2018-01-19 | 16,249 | $0.00 | 16,249 | $16.14 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 42,195 | 2019-02-15 | No | 4 | M | Direct |
Footnotes
- The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.81 to $152.24, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 2/15/09.
Billionaire Hedge Funds
